SCHEMBL1447405

SCHEMBL1447405

Cc1oncc1NC(=O)C1CCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
CSF1R P07333 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.46
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
NPSR1 Q6W5P4 2/20 0.44
RAB9A P51151 2/20 0.42
TSHR P16473 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TAS2R8 Q9NYW2 1/20 0.41
MEN1 O00255 1/20 0.41
CETP P11597 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
ATAD2 Q6PL18 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060937 0.76 CSF1R (0.58) LMNACSF1RSMN1; SMN2KMT2AALDH1A1
SCHEMBL11016941 0.74 CSF1R (0.57) LMNACSF1RSMN1; SMN2ALDH1A1KDM4E
SCHEMBL4023454 0.71 LMNA (0.50) LMNACSF1RSMN1; SMN2GAAALDH1A1
SCHEMBL29856319 0.71 MAPT (0.62) LMNAKMT2AGAAALDH1A1KDM4E
SCHEMBL11022041 0.70 CSF1R (0.53) LMNACSF1RSMN1; SMN2KMT2AALDH1A1
SCHEMBL6105948 0.69 CSF1R (0.51) LMNACSF1RSMN1; SMN2KMT2ANPSR1
SCHEMBL22133040 0.68 CCNA2 (0.55) LMNASMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL4026866 0.67 LMNA (0.41) LMNACSF1RSMN1; SMN2ALDH1A1TSHR
SCHEMBL23863559 0.67 KMT2A (0.50) LMNASMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL16568954 0.67 KMT2A (0.54) LMNASMN1; SMN2KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2301928-A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders AstraZeneca AB (SE) 2011-03-30 EP disclosed
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders ASTRAZENECA AB (SE) 2008-11-13 US disclosed
EP-1912974-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2008-04-23 EP disclosed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders CCNI, MKI67, TYMP LMNA 1429/4885CSF1R 3994/4885SMN1; SMN2 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.